JUST IN: Clinical trials for Oxford's COVID-19 vaccine have been put on hold due to a “potentially unexplained illness in one of the trials,” AstraZeneca says Tuesday.
AstraZeneca, which is working with the University of Oxford on a coronavirus vaccine, began its phase 3 clinical trials in the U.S. last week. NBC News has confirmed that the pause has affected trial sites in the U.S.began their phase 3 trials in late July and have already enrolled about 30,000 volunteers.
The Oxford vaccine uses a type of virus called an adenovirus to teach the immune system how to make antibodies to attack the coronavirus' so-called spike protein. It's that spike protein that allows the virus to infect human cells.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
COVID vaccine candidate developed by Oxford University and AstraZeneca put on hold after 'unexplained illness'Drug giant AstraZeneca is reviewing the event that caused the illness during Phase 3 of Oxford's COVID-19 vaccine trials. The interruption represents the first major hiccup in what has been a smooth path in the rapid vaccine effort spanning the globe.
Weiterlesen »
AstraZeneca shares drop 6% after company announces 'routine' safety pause in vaccine trial
Weiterlesen »
COVID vaccine candidate developed by Oxford University and AstraZeneca put on hold after 'unexplained illness'Drug giant AstraZeneca is reviewing the event that caused the illness during Phase 3 of Oxford's COVID-19 vaccine trials. The interruption represents the first major hiccup in what has been a smooth path in the rapid vaccine effort spanning the globe.
Weiterlesen »
Coronavirus live updates: Major late-stage vaccine trial paused; drugmakers pledge to prioritize safetyThe coronavirus has infected more than 27.4 million people around the world so far, killing at least 893,871 people.
Weiterlesen »
Drug company CEOs issue vaccine safety pledgeThe chief executives of nine drug companies pledged Tuesday not to seek regulatory approval before the safety and efficacy of their experimental coronavirus vaccines have been established in Phase 3 clinical trials, according to reporting.
Weiterlesen »
COVID-19 vaccine makers issue rare safety pledge as fears of political pressures swirlA coalition of pharmaceutical chief executives issue a joint pledge that they will not rush the development of a COVID-19 vaccination for political purposes and will not seek approvals until the vaccines have gone through Phase 3 clinical trials.
Weiterlesen »